series. 89 Risk factors for CVST are similar to risk factors for all venous thrombotic disorders and include oral contraceptive or hormone therapy, steroids, infection, malignancy, trauma, pregnancy, underlying hematological disorder, vasculitis, and mechanical precipitants (for example, lumbar puncture and neurosurgery). 16, 17, 77 Although almost 25% of cases will have no clear cause even after an extensive workup, 2 CVST is extremely variable in its clinical presentation. Headache is the most common clinical symptom, occurring in 75-95% of all cases. 2, 16, 21 Other symptoms and signs include visual loss, papilledema, diplopia, stupor, motor deficits, seizures, coma, and death. 21, 34 Diagnosis is confirmed by angiography, CT venography, and/or MR imaging. * AVF = arteriovenous fistula; deterior = deterioration; FU = follow-up; improve = improvement; mod = moderate; neuro = neurological; NR = not reported; ped = pediatric; strepto = streptokinase; uro = urokinase.
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The diagnosis of CVST continues to be elusive given the wide spectrum of clinical signs and symptoms, subacute to chronic onset, imaging appearance, and outcome. However, given the possibility for serious morbidity and mortality, timely treatment is critical. First-line treatment is systemic anticoagulation with studies demonstrating improved neurological outcomes in patients who received systemic heparin compared with controls. 22, 28, 40 Heparin has also been found to be safe in the treatment of CVST in the setting of ICH.
22,28 After the acute period, patients are usually switched to oral anticoagulation for 3-12 months depending on the cause of CVST.
33, 62 Additionally, patients may require concomitant treatment for CVST complications including seizures and intracranial hypertension. However, even with these measures, some patients continue to decline or fail to improve. These cases have been shown to benefit from thrombolysis and thrombectomy. Most reports of the use of thrombolysis for CVST have described direct infusion with a microcatheter, although some cases were treated with systemic delivery. In a systemic review published in 2003 comparing 118 patients who were treated with local thrombolysis with 15 patients treated with systemic thrombolysis, the groups did not differ in terms of the rates of death, dependency, hemorrhages, or other complications. 11 However, the systemic thrombolysis group was more likely to have only partial or no recanalization (OR 8.9, 95% CI 2.4-33.8).
Direct Thrombolysis
Systemic thrombolysis in the treatment of CVST was first described by Vines and Davis 91 in 1971 with intravenous infusion of urokinase in 5 patients. Since the development of endovascular access to cerebrovascular disease, most reports of thrombolysis in the treatment of CVST involve direct infusion of thrombolytics. In the English-language literature, 70 publications have described direct infusion of various thrombolytics in the treatment of CVST. The early reports consist of case reports or small series that used urokinase in adults or children. These reports demonstrated excellent to good outcomes in 140 of 161 patients, even if direct thrombolysis was performed after prolonged treatment with systemic anticoagulation (up to 3 months). 82 Additionally, thrombolytic infusion was found to be safe in the setting of preexisting ICH, 47 similar to treatment with systemic anticoagulation.
22,28 Most of the publications described a transfemoral approach, although some clinicians accessed the venous sinuses via a fontanelle puncture, bur holes, or craniotomy. 3, 29, 44, 56, 70, 78 The dose of urokinase varied. Many regimens involved a bolus at the time of the intervention, followed by a continuous infusion by leaving the catheter in place. 8, 47, 78, 82 These patients underwent frequent venography to assess the status of the thrombosis. Other authors have described only a bolus 90 or a continuous infusion. 7, 44 Two reports described treatment with streptokinase 52,70 and 15 described treatment with tPA. 92 conducted a retrospective study to compare the efficacy of systemic heparin with that of direct chemical thrombolysis. The heparin group (20 patients) and thrombolysis group (20 patients) were at 2 different institutions, and the thrombolysis group did not receive heparin. The neurological function was worse in thrombolysis group before treatment, but it was better than the heparin group at the time of discharge (p = 0.019). Hemorrhagic complications were observed in 10% (2 patients) of the thrombolysis group compared with 0% of the heparin group. These results were promising for thrombolysis alone. However, further prospective trials have not been conducted, and most institutions continue to combine direct thrombolysis with systemic anticoagulation. Moreover, with the advent of sophisticated endovascular techniques, many have combined chemical thrombolysis and systemic anticoagulation with mechanical thrombectomy.
Mechanical Thrombolysis/Thrombectomy
Twenty publications have described mechanical throm bolysis/thrombectomy in 34 patients. All but 3 of these studies used mechanical techniques in combination with thrombolytics. 12, 49, 59 Two patients underwent craniotomy and direct dural sinus access of the catheter for endovascular thrombectomy. 12 Generally, the thrombolytics were given as a bolus during the procedure and in some cases, followed by continuous infusion. Many of the publications reported balloon angioplasty or use of a rheolytic catheter to break up the clot. 5, 9, 12, 13, 15, 19, 25, 43, 68, 72, 97 Two reports described balloon angioplasty with stent placement. 49, 59 In 1 case, the patient initially underwent balloon angioplasty alone. 59 However, after initial improvement, the 13-year-old patient experienced worsening episodes of aphasia and underwent angiography, which revealed reocclusion. He subsequently underwent further balloon angioplasty and stent placement in his occipital sinus. He was discharged home on a regimen of warfarin, ticlopidine, and aspirin, and he did not suffer any neurological deficits. The second report involved 2 patients who underwent balloon angioplasty of the transverse sinus with significant improvement in sinus venous pressure and the patients' vision. 49 The only prospective study of CVST endovascular treatment enrolled 20 patients with a mean age of 32 years. 85 Patients were selected for endovascular intervention if they had an altered mental status, straight sinus thrombosis, or large mass lesion. The study patients were mostly critically ill prior to treatment; 12 of the patients were comatose, 14 had hemorrhagic infarcts, and 11 had deep cerebral thrombosis. Fifteen patients underwent urokinase thrombolysis with thrombosuction using a rheolytic catheter, 4 underwent thrombolysis only, and 1 patient did not undergo any intervention because of difficulty in accessing the sinus. Nine patients recovered or had minimal symptoms, 3 had a minor handicap, and 2 had a moderate or severe handicap as measured using the Rankin scale. The 6 patients who died were more likely to have leukemia (3 of 6) and or large hemorrhagic infarcts (4 of 6). Five patients had increased cerebral hemorrhage (3 minor and 2 major) after endovascular treatment, and 4 of these patients died. Although the authors noted that they believed that only 1 of these patients died of increase in ICH size, the other 4 patients were in critical condition prior to intervention. 85 This study demonstrated the significant morbidity and mortality that can be associated with CVST. Due to selection of a severely compromised patient population, the outcomes in this study were much worse than those in previous reports. However, despite the severe nature of the enrolled patients' CVSTs, many of the patients experienced a remarkable recovery, with 12 achieving almost complete recovery.
A large portion of the patients in the literature who were treated with thrombolytics were encephalopathic or comatose at the time of treatment, but they had excellent outcomes. Although promising, the results of direct thrombolysis and thrombectomy must be interpreted cautiously. The studies are mostly case reports, without standard reporting of treatment and outcome measures. Other therapy such as barbiturate coma or craniectomy may have also benefited the patients. Additionally, publication bias has most likely selected for publications with good outcomes. The authors of a review published in the Cochrane Database in 2004 concluded that the current evidence could not support the routine use of thrombolytics in the treatment of CVST. They discouraged further publications of case reports of this treatment and encouraged an RCT. An RCT analyzing vessel patency and/or complications after direct thrombolysis/thrombectomy would be useful in validating this treatment for CVST. On the other hand, an RCT measuring clinical efficacy would require a large sample size and multicenter collaboration, making it a more formidable undertaking. Based on our interpretation of the current literature, we have devised a treatment algorithm for our patients (Fig. 1) . Patients who present with severe neurological deficits (GCS score ≤ 8) are strongly considered for direct thrombolysis/thrombectomy immediately. Patients with GCS scores between 9 and 12 may be considered for immediate endovascular treatment. For other patients (GCS score > 12), direct thrombolysis/thrombectomy would be considered only after a trial of systemic anticoagulation. Although useful, this algorithm can only be validated with a properly designed prospective study.
Conclusions
Cerebral venous sinus thrombosis is an increasingly recognized cause of neurological illness with a range of clinical symptoms. Standard treatment is systemic anticoagulation. However, in a subset of patients who decline despite adequate treatment or have a dramatic initial presentation, direct thrombolysis/thrombectomy may be performed. Small case series and prospective studies have demonstrated safety and good initial results with direct thrombolytic infusions, mechanical thrombectomy, and stenting. Well-designed prospective studies are necessary to further investigate endovascular treatment as standard of care for patients with CVST.
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